natgillin/translations-raw huggingface dataset:
Adverse reactions reported in all clinical trials and occurring more frequently (p ≤0.05) with telmisartan plus hydrochlorothiazide than with placebo are shown below according to system organ class.
Nuspojave prijavljene u svim kliničkim ispitivanjima i one koje se češće javljaju (p ≤ 0,05) pri kombinaciji telmisartan plus hidroklorotiazid nego uz placebo prikazane su u nastavku, klasificirane prema organskim sustavima.
Adverse reactions reported in all clinical trials with Jentadueto are shown below according to system organ class.
Nuspojave prijavljene u svim kliničkim ispitivanjima s Jentaduetom navedene su u nastavku prema organskim sustavima.
Adverse reactions reported in all CML and Ph+ ALL patients are presented in Table 4.
Nuspojave prijavljene kod svih KML i Ph+ ALL bolesnika prikazane su u Tablici 4.
Adverse reactions reported in at least
Nuspojave prijavljene u najmanje
Adverse reactions reported in at least 2 patients are listed in Table 1.
Nuspojave prijavljene u najmanje 2 bolesnika navedene su u Tablici 1.
Adverse reactions reported in CKD 5D and CKD ND patients are presented in Tables 1 and 2, respectively.
Nuspojave prijavljene u bolesnika s KBB 5D i KBB ND prikazane su u Tablici 1., odnosno Tablici 2.
Adverse reactions reported in clinical studies and in postmarketing reports
Nuspojave zabilježene u kliničkim ispitivanjima i izvješćima nakon stavljanja lijeka u promet
Adverse reactions reported in patients with advanced melanoma who were treated with ipilimumab 3 mg/kg in clinical trials (n= 767) are presented in Table 2.
Nuspojave zabilježene u bolesnika s uznapredovalim melanomom koji su bili liječeni lijekom ipilimumabom u dozi od 3 mg/kg u kliničkim ispitivanjima (n= 767) prikazane su u tablici 2.
Adverse reactions reported in phosphate containing eye drops:
Nuspojave prijavljene pri primjeni kapi koje sadrže fosfat
Adverse reactions reported in rheumatoid arthritis clinical trials and postmarketing cases at least possibly related to Cimzia are listed in Table 1 below, according to frequency and system organ class.
Nuspojave zabilježene u kliničkim istraživanjima za reumatoidni artritis i postmarketinški slučajevi za koje postoji mogućnost da su povezani s primjenom Cimzije navedeni su u Tablici 1 prema učestalosti i klasifikaciji organskih sustava.
Adverse reactions reported in subjects who received Naltrexone/Bupropion, Naltrexone and Bupropion
Nuspojave prijavljene u ispitanika koji su primali naltrekson/bupropion, naltrekson i bupropion
Adverse reactions reported in the double-blind period of the Phase 3 study
Nuspojave prijavljene u dvostruko slijepom razdoblju ispitivanja faze III
Adverse reactions reported in the paediatric population were, in general, similar to those reported in adults.
Nuspojave prijavljene u pedijatrijskoj populaciji općenito su bile slične onima u odraslih.
Adverse reactions reported in the pooled dataset for patients treated with nivolumab monotherapy (n=1728) and for patients treated with nivolumab in combination with ipilimumab (n=448) are presented in Table 2.
U Tablici 2 prikazane su nuspojave prijavljene u objedinjenim podacima prikupljenima u bolesnika liječenih monoterapijom nivolumabom (n = 1728) i bolesnika liječenih nivolumabom u kombinaciji s ipilimumabom (n = 448).
Adverse reactions reported in ≥ 1% of patients with soft tissue sarcoma in clinical trials.
Nuspojave prijavljene u ≥ 1 % bolesnika sa sarkomom mekih tkiva u kliničkim ispitivanjima.
Adverse reactions reported in ≥ 5% of patients in clinical trial ET743-OVA-301
Nuspojave prijavljene u ≥ 5 % bolesnica u kliničkom ispitivanju ET743-OVA-301
Adverse reactions reported in ≥ 5% of patients treated with saxagliptin 5 mg and more commonly than in patients treated with placebo or that were reported in ≥ 2% of patients treated with saxagliptin 5 mg and ≥ 1% more frequently compared to placebo are shown in Table 1.
U Tablici 1 prikazane su nuspojave prijavljene u ≥ 5% bolesnika liječenih saksagliptinom od 5 mg, češće nego u bolesnika koji su primali placebo, odnosno nuspojave prijavljene u ≥ 2% bolesnika liječenih saksagliptinom u dozi od 5 mg te ≥ 1% češće u usporedbi s placebom.
Adverse reactions reported in ≥ 5% of patients treated with saxagliptin 5 mg and more commonly than in patients treated with placebo or that were reported in ≥ 2% of patients treated with saxagliptin 5 mg and ≥ 1% more frequently compared to placebo from the pooled analysis of five studies of glycaemic control, plus an additional active-controlled study of initial combination with metformin are shown in Table 1.
U Tablici 1 prikazane su nuspojave zabilježene u ≥ 5% bolesnika liječenih saksagliptinom od 5 mg i češće nego u bolesnika koji su primali placebo, ili one prijavljene u ≥ 2% bolesnika liječenih saksagliptinom od 5 mg i ≥ 1% češće nego u onih koji su primali placebo u analizi objedinjenih podataka iz pet ispitivanja regulacije glikemije i jednog dodatnog, aktivnim lijekom kontroliranog ispitivanja početne kombinacije s metforminom.
Adverse reactions reported up to the cut-off date of the analysis are presented in Table 1.
Nuspojave prijavljene do isključnog datuma za analizu navedene su u Tablici 1.
Adverse reactions reported when linagliptin and metformin were combined with insulin
Nuspojave prijavljene kada su linagliptin i metformin bili kombinirani s inzulinom
Adverse reactions reported when linagliptin and metformin were combined with insulin
Nuspojave prijavljene kada su linagliptin i metformin kombinirani s inzulinom
Adverse reactions reported when linagliptin and metformin were combined with sulphonylurea
Nuspojave prijavljene kada su linagliptin i metformin kombinirani sa sulfonilurejom
Adverse reactions reported with an incidence greater than placebo, during the Lennox-Gastaut syndrome double-blind studies or in the overall rufinamide-exposed population, are listed in the table below by MedDRA preferred term, system organ class and by frequency.
Nuspojave za koje je zabilježena incidencija veća od one uz placebo, u dvostruko slijepim ispitivanjima u bolesnika s Lennox-Gastautovim sindromom i ukupnoj populaciji izloženoj rufinamidu, navedene su u sljedećoj tablici prema MedDRA standardnim izrazima, klasifikaciji organskih sustava i učestalosti.
Adverse reactions reported with ofatumumab in previously untreated and relapsed or refractory CLL patients, either alone or in combination with an alkylating agent, are listed below by MedDRA body system organ class and by frequency.
Nuspojave prijavljene tijekom primjene ofatumumaba u bolesnika koji prethodno nisu liječeni, s relapsnim ili refraktornim KLL-om, bilo samog ili u kombinaciji s alkilirajućim lijekom, navode se u nastavku i to prema MedDRA klasifikaciji organskih sustava i učestalosti.
Adverse reactions reported with one of the individual components may be potential adverse reactions with Actelsar HCT, even if not observed in clinical trials with this product.
Nuspojave prijavljene uz jednu od pojedinih komponenti mogu biti potencijalne nuspojave uz Actelsar HCT, čak ako i nisu primijećene u kliničkim ispitivanjima s ovim lijekom.
Adverse reactions reported with one of the individual components may be potential adverse reactions with PritorPlus, even if not observed in clinical trials with this product.
Nuspojave prijavljene uz jednu od pojedinih komponenti mogu biti potencijalne nuspojave uz PritorPlus, čak ako i nisu primijećene u kliničkim ispitivanjima s ovim lijekom.
Adverse reactions reported with the fixed dose combination
Nuspojave prijavljene s fiksnom kombinacijom doze
Adverse reactions reported with the fixed dose combination
Nuspojave prijavljene uz fiksnu kombinaciju doza
Adverse reactions reported with the use of hydrochorothiazide alone
Nuspojave (bez obzira na povezanost s lijekom) prijavljene pri primjeni samo hidroklorotiazida
Adverse reactions reported with the use of irbesartan alone
Nuspojave prijavljene samo za irbesartan
Adverse reactions seen with olanzapine
Nuspojave primijećene kod primjene olanzapina
Adverse reactions such as chills, headache, dizziness, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally in connection with intravenous administration of human immunoglobulin including Privigen.
Nuspojave kao što su zimica, glavobolja, omaglica, vrućica, povraćanje, alergijske reakcije, mučnina, artralgija, niski krvni tlak te umjerena bol u donjem dijelu leđa mogu se pojaviti u povezanosti s intravenskom primjenom ljudskog imunoglobulina, uključujući Privigen.
Adverse reactions such as chills, headache, dizziness, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.
Povremeno se mogu se pojaviti nuspojave kao što su zimica, glavobolja, omaglica, vrućica, povraćanje, alergijske reakcije, mučnina, artralgija, niski krvni tlak te umjerena bol u donjem dijelu leđa.
Adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia (joint pain), low blood pressure and moderate low back pain may occur occasionally.
Povremeno se mogu pojaviti nuspojave kao što su zimica, glavobolja, vrućica, povraćanje, alergijske reakcije, mučnina, artralgija (bol u zglobovima), nizak krvni tlak i umjerena bol u donjem dijelu leđa.
Adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.
Povremeno se mogu pojaviti nuspojave kao što su drhtavica, glavobolja, groznica, povraćanje, alergijske reakcije, mučnina, artralgija, nizak krvni tlak i umjerena bol u križima.
Adverse reactions such as oesophagitis, oesophageal ulcers and oesophageal erosions, in some cases severe and requiring hospitalisation, rarely with bleeding or followed by oesophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates.
U bolesnika koji peroralno uzimaju bisfosfonate prijavljeni su štetni događaji kao što su ezofagitis, ulkusi jednjaka i erozije jednjaka, koji su u nekim slučajevima bili teški i zahtijevali su bolničko liječenje, rijetko s krvarenjem ili praćeni strikturom jednjaka ili perforacijom.
Adverse reactions such as: vomiting, diarrhoea, lack of energy, decreased appetite and itching were uncommonly observed.
Nuspojave poput povraćanja, proljeva, gubitka energije, smanjenog apetita i svraba nisu često zamijećene.
Adverse reactions such as: vomiting, diarrhoea, lethargy, anorexia, and pruritus were uncommonly observed.
Nuspojave poput povraćanja, proljeva, letargije, anoreksije i pruritusa nisu često zamijećene.
Adverse reactions that have been observed with bazedoxifene monotherapy
Nuspojave opažene kod monoterapije bazedoksifenom.
Adverse reactions that have been observed with CE monotherapy
Nuspojave opažene kod monoterapije KE.
Adverse reactions that may suggest increase in prolactin levels (e.g. amenorrhoea, galactorrhoea, menstrual disturbances, gynaecomastia) were reported overall in < 1% of subjects.
Nuspojave koje mogu ukazivati na porast razine prolaktina (npr. amenoreja, galaktoreja, poremećaj menstruacije i ginekomastija) ukupno su zabilježene u < 1% ispitanika.
Adverse reactions that most commonly led to dose reductions (in ≥5% of patients) were hypertension, proteinuria, diarrhoea, fatigue, PPE, weight decreased, and decreased appetite.
Nuspojave koje su najčešće dovele do sniženja doze (u ≥5% bolesnika) bile su hipertenzija, proteinurija, proljev, umor, PPE, smanjena tjelesna težina i smanjeni apetit.
Adverse reactions that occurred during clinical studies or that were spontaneously reported from post- marketing experience are listed by frequency in the table below.
Nuspojave iz kliničkih ispitivanja ili one koje su spontano prijavljene nakon stavljanja lijeka u promet navedene su prema učestalosti u tablici u nastavku.
Adverse reactions that occurred with clopidogrel alone, with ASA alone* or with clopidogrel in combination with ASA either during clinical studies or that were spontaneously reported are presented in the table below.
Nuspojave koje su se pojavile pri primjeni klopidogrela u monoterapiji, ASK u monoterapiji* ili klopidogrela u kombinaciji s ASK prijavljene ili tijekom kliničkih ispitivanja ili spontano navedene su u tablici.
Adverse reactions that were reported in post-marketing experience are listed below (Table 2), by system organ class and frequency as follows:
Nuspojave zabilježene nakon stavljanja lijeka u promet navedene su niže (tablica 2) prema klasifikaciji organskih sustava i učestalosti kako slijedi:
Adverse reactions that were reported in RCC and MCL patients in the phase 3 studies are listed below (Table 1), by system organ class, frequency and grade of severity (NCI-CTCAE).
Nuspojave koje su bile zabilježene u bolesnika s karcinomom bubrežnih stanica i limfomom plaštenih stanica u fazi III ispitivanja navedene su niže (tablica 1) prema klasifikaciji organskih sustava, učestalosti i stupnju težine (NCI-CTCAE).
Adverse reactions that were reported most commonly ≤ 1 day following a leukapheresis procedure in controlled clinical trials included citrate toxicity (14.6%), oral paraesthesia (12.0%), and paraesthesia (11.1%).
Nuspojave koje su najčešće prijavljene ≤ 1 dan nakon postupka leukafereze u kontroliranim kliničkim ispitivanjima uključivale su citratnu toksičnost (14,6%), oralne parestezije (12,0%) i parestezije (11,1%).
Adverse reactions to cobicistat-boosted atazanavir during 144 weeks of clinical trial experience from study GS-US-216-0114 are listed in Table 3, below, by body system organ class and frequency.
Nuspojave na kobicistatom pojačani atazanavir tijekom 144 tjedna iskustva kliničkih ispitivanja iz ispitivanja GS-US-216-0114 navedene su u Tablici 3, u nastavku prema klasifikaciji sustava organa i učestalosti.
Adverse reactions to orlistat are largely gastrointestinal in nature and related to the pharmacologic effect of the medicinal product on preventing the absorption of ingested fat.
Nuspojave pri uzimanju orlistata po svojoj su naravi uglavnom gastrointestinalne, i povezane s farmakološkim učinkom lijeka koji se očituje sprječavanjem apsorpcije unesene masti.
Adverse reactions to orlistat are largely gastrointestinal in nature.
Nuspojave orlistata uglavnom su gastrointestinalne naravi.
Adverse reactions to Stribild from Phase 3 clinical studies GS-US-236-0102 and GS-US-236-0103 and adverse reactions to treatment with emtricitabine and tenofovir disoproxil fumarate from clinical studies and post-marketing experience, when used with other antiretrovirals, are listed in Table 2, below, by body system organ class and highest frequency observed.
Nuspojave na Stribild zabilježene u fazi 3 kliničkih ispitivanja GS-US-236-0102 i GS-US-236-0103 i nuspojave na liječenje emtricitabinom i tenofovirdizoproksilfumaratom iz kliničkih ispitivanja i iskustva nakon stavljanja lijeka u promet, u uporabi s drugim antiretrovirusnim lijekovima, navedene su niže u Tablici 2 po organskim sustavima i najvišoj uočenoj učestalosti.
Adverse reactions were categorized as very common (( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100), rare ( 1/10,000 to < 1/1,000), very rare (< 1/10,000) or not known (cannot be estimated from available data).
Nuspojave su kategorizirane kao vrlo često (( 1/10), često ( 1/100 to < 1/10), manje često ( 1/1000 to < 1/100), rijetko ( 1/10000 to < 1/1000), vrlo rijetko (< 1/10000) ili nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions were determined based on pooled data from seven randomised, double-blind, placebo-controlled studies of Aranesp with a total of 2112 patients (Aranesp 1200, placebo 912).
Nuspojave su određene na temelju prikupljenih podataka iz sedam randominiziranih dvostruko slijepih, placebom kontroliranih ispitivanja Aranespa s ukupno 2112 bolesnika (Aranesp 1200, placebo 912).
Adverse reactions were more frequent in females and in patients more than 65 years of age in both the bivalirudin and the heparin-treated comparator groups compared to male or younger patients.
U usporedbi s muškim ili mlađim bolesnicima, nuspojave su bile učestalije u žena i bolesnika starijih od 65 godina u obje uspoređivane grupe ispitanika (liječeni bivalirudinom ili heparinom).
Adverse reactions were mostly mild to moderate in intensity and almost all occurred during the infusion or during the 2 hours following the infusion (infusion associated reactions, IARs).
Nuspojave su uglavnom bile blagog do umjerenog intenziteta i gotovo su sve nastupile tijekom infuzije ili unutar 2 sata nakon primjene infuzije (reakcije povezane s infuzijom).
Adverse reactions were observed in embryotoxicity studies in the rabbit.
Nuspojave su primijećene u ispitivanjima embriotoksičnosti u kuniću.
Adverse reactions were reported at a similar frequency for the Ipreziv 20 mg dose as with the 40 and 80 mg doses in one placebo controlled study.
U jednom kliničkom ispitivanju kontroliranom placebom, nuspojave su bile zabilježene sličnom učestalošću kako za dozu Ipreziva od 20 mg, tako za doze od 40 i 80 mg.
Adverse reactions were reported in 93% of Benlysta-treated patients and 92% of placebo-treated patients.
Nuspojave su bile prijavljene u 93% bolesnika liječenih lijekom Benlysta, te u 92% bolesnika liječenih placebom.
Adverse reactions were typically mild to moderate and seldom led to discontinuation.
Nuspojave su bile tipično blage do umjerene i rijetko su vodile do prekida terapije.
Adverse reactions were usually mild or moderate and occurred within the first two weeks of treatment.
Nuspojave su bile obično blage ili umjerene i pojavljivale su se unutar prva dva tjedna liječenja.
Adverse reactions were usually mild or moderate and occurred within the first two weeks of treatment.
Nuspojave su bile obično blage ili umjerene te su se javile unutar prva dva tjedna liječenja.
Adverse reactions which occurred in > 1 % of Revatio-treated patients and were more frequent (> 1 % difference) on Revatio in the pivotal study or in the Revatio combined data set of both the placebo-controlled studies in pulmonary arterial hypertension, at doses of 20, 40 or 80 mg TID are listed in the table below by class and frequency grouping (very common ( 1/10), common ( 1/100 to
U sljedećoj su tablici navedene nuspojave koje su nastupile u > 1% bolesnika liječenih lijekom Revatio i koje su se javile češće (razlika > 1%) uz primjenu lijeka Revatio u dozama od 20, 40 ili 80 mg TID u pivotalnom ispitivanju ili u kombiniranim podacima iz oba placebom kontrolirana ispitivanja u plućnoj arterijskoj hipertenziji.
Adverse reactions which occurred in > 1 % of Revatio-treated patients and were more frequent (> 1 % difference) on Revatio in the pivotal study or in the Revatio combined data set of both the placebo-controlled studies in pulmonary arterial hypertension,, at doses of 20, 40 or 80 mg TID are listed in the table below by class and frequency grouping (very common ( 1/10), common ( 1/100 to
U sljedećoj su tablici navedene nuspojave koje su nastupile u > 1% bolesnika liječenih lijekom Revatio i koje su se javile češće (razlika > 1%) uz primjenu lijeka Revatio u dozama od 20, 40 ili 80 mg TID u pivotalnom ispitivanju ili u kombiniranim podacima iz oba placebom kontrolirana ispitivanja u plućnoj arterijskoj hipertenziji.
Adverse reactions with asfotase alfa are listed by system organ class and preferred term using MedDRA frequency convention very common (1/10), common (1/100 to <1/10), uncommon (1/1,000 to <1/100), rare (1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data).
Nuspojave opažene za asfotazu alfa navedene su prema klasifikaciji organskih sustava i preporučenom izrazu na temelju MedDRA-inog prikaza učestalosti nuspojava kao vrlo često (1/10), često (1/100 i <1/10), manje često (1/1000 i <1/100), rijetko (1/10 000 i <1/1000), vrlo rijetko (<1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions with at least 2% difference over placebo are in italics.
Nuspojave s najmanje 2 % razlike u odnosu na placebo su označene kurzivom.
Adverse reactions with at least 2% difference over placebo are in italics.
Nuspojave s najmanje 2% razlike u odnosu na placebo su označene kurzivom.
Adverse reactions with at least 2% difference over placebo are marked in italics.
Nuspojave s najmanje 2 % razlike u odnosu na placebo su označene kurzivom.
Adverse reactions with BRINAVESS *
Nuspojave lijeka BRINAVESS
Adverse Reactions – all Grades
Nuspojave – svi stupnjevi
Adverse Reactions – Neurosurgery
Nuspojave – neurokirurgija
Adverse Reactions – Vascular Surgery
Nuspojave – kirurgija krvnih žila
ADVERSE REACTIONS*
NUSPOJAVE
Adverse reactions, considered at least possibly attributable to cinacalcet treatment in the placebo controlled studies and single-arm studies based on best-evidence assessment of causality are listed below using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
Nuspojave, za koje se smatra da postoji barem mogućnost da se mogu pripisati liječenju sinakalcetom u placebom kontroliranim ispitivanjima i ispitivanjima na jednoj skupini prema procjeni uzročno- posljedične veze na temelju najboljih dokaza navedene su niže prema sljedećoj konvenciji: vrlo često (≥ 1/10); često (≥ 1/100 i < 1/10); manje često (≥ 1/1000 i < 1/100); rijetko (≥ 1/10 000 i < 1/1000); vrlo rijetko (< 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse Reactions, Probably or Possibly Related to CellCept, Reported in Patients Treated with CellCept in Renal and Hepatic Clinical Trials when Used in Combination with Ciclosporin and Corticosteroids
Nuspojave, vjerojatno ili moguće povezane s lijekom CellCept, prijavljene u ispitivanjima kod bolesnika s presađenim bubregom i jetrom liječenih lijekom CellCept u kombinaciji s ciklosporinom i kortikosteroidima
Adverse Reactions, Probably or Possibly Related to CellCept, Reported in Patients Treated with CellCept in Renal, Cardiac and Hepatic Clinical Trials when Used in Combination with Ciclosporin and Corticosteroids
Nuspojave, vjerojatno ili moguće povezane s lijekom CellCept, prijavljene u ispitivanjima kod bolesnika s presađenim bubregom, srcem i jetrom liječenih lijekom CellCept u kombinaciji s ciklosporinom i kortikosteroidima
Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of zoledronic acid along with driving and operating of machinery.
Nuspojave poput omaglice i pospanosti mogu utjecati na sposobnost upravljanja vozilima i rada sa strojevima te je stoga potreban oprez kad se tijekom primanja zoledronatne kiseline upravlja vozilima i radi sa strojevima.
Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of zoledronic acid along with driving and operating of machinery.
Nuspojave poput omaglice i somnolencije mogu utjecati na sposobnost upravljanja vozilima i rada na strojevima te je stoga potreban oprez kad se tijekom primjene zoledronatne kiseline upravlja vozilima i radi na strojevima.
Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of Zoledronic acid Mylan along with driving and operating of machinery.
Nuspojave poput omaglice i pospanosti mogu utjecati na sposobnost upravljanja vozilima i rada sa strojevima te je stoga potreban oprez kad se tijekom primanja Zoledronatne kiseline Mylan upravlja vozilima i radi sa strojevima.
Adverse reactions, such as dizziness, may affect the ability to drive or use machines, though no studies on this effect with zoledronic acid have been performed.
Nuspojave poput omaglice i somnolencije mogu utjecati na sposobnost upravljanja vozilima i rada na strojevima te je stoga potreban oprez kad se tijekom primjene zoledronatne kiseline upravlja vozilima i radi na strojevima.